HER2 assessment in bladder cancer is conducted similarly to breast cancer, utilizing IHC to evaluate protein overexpression and fluorescence in situ hybridization (FISH) for gene amplification. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.